Evidence map›Paper›PMID 29229594›Full record

Trial reportBlood2018

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

Alex F Herrera, Alison J Moskowitz, Nancy L Bartlett, Julie M Vose, Radhakrishnan Ramchandren, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H Moskowitz, Keenan Fenton and 6 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02572167 (A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy), which is not on this map. Cited by 160 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 3 pooled it
29.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02572167 phase1 / phase2completednot on this map

A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

TypeinterventionalSponsorSeagen Inc.Ran2015 to 2021Enrolled93ConditionsHodgkin LymphomaArmsbrentuximab vedotin, nivolumab
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 3 syntheses or guidelines pooled it, 318 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  20. Trial

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Alex F HerreraCity of Hope National Medical Center, Duarte, CA.
Alison J MoskowitzMemorial Sloan Kettering Cancer Center, New York, NY.
Nancy L BartlettDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.
Julie M VoseUniversity of Nebraska Medical Center, Omaha, NE.
Radhakrishnan RamchandrenKarmanos Cancer Institute, Detroit, MI.
Tatyana A FeldmanHackensack University Medical Center, Hackensack, NJ.
Ann S LaCasceDana-Farber Cancer Institute, Boston, MA.
Stephen M AnsellMayo Clinic, Rochester, MN.
Craig H MoskowitzMemorial Sloan Kettering Cancer Center, New York, NY.
Keenan FentonSeattle Genetics, Inc, Bothell, WA.
Carol Anne OgdenSeattle Genetics, Inc, Bothell, WA.
David TaftSeattle Genetics, Inc, Bothell, WA.
Qu ZhangSeattle Genetics, Inc, Bothell, WA.
Kazunobu KatoBristol-Myers Squibb, Princeton, NJ; and.
Mary CampbellSeattle Genetics, Inc, Bothell, WA.
Ranjana H AdvaniStanford University Medical Center, Palo Alto, CA.
Seagen (United States) · USMemorial Sloan Kettering Cancer Center · USBristol-Myers Squibb (United States) · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · USHackensack University Medical Center · USMayo Clinic in Arizona · USStanford Medicine · USThe Barbara Ann Karmanos Cancer Institute · USUniversity of Nebraska Medical Center · USWashington University in St. Louis · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI KWAK, LARRY W · 2004 to 2022
$35.5M
Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
NCI NIH HHS K12 CA001727NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of combination treatment, with BV administered on day 1 and Nivo on day 8 of the first cycle. For cycles 2 to 4, BV and Nivo were both administered on day 1. After study treatment, responses were evaluated by investigators per the 2014 Lugano classification, and patients could proceed to autologous stem cell transplantation (ASCT). Sixty-two patients were enrolled; the complete response rate among all treated patients (n = 61) was 61%, with an objective response rate of 82%. Before ASCT, adverse events (AEs) occurred in 98% of patients, mostly grades 1 and 2. Infusion-related reactions (IRRs) occurred in 44% of patients overall, with 41% of patients experiencing an IRR during at least 1 infusion of BV. Five patients (8%) were treated with systemic steroids for immune-related AEs. A reduction of peripheral T-cell subsets including regulatory T cells was observed after the first dose of BV, and reduced serum levels of thymus- and activation-regulated chemokine concurrent with an increase in proinflammatory cytokines and chemokines were seen after the first BV plus Nivo infusions. The combination of BV plus Nivo was an active and well-tolerated first salvage regimen, potentially providing patients with R/R HL an alternative to traditional chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT02572167.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinChemokinesFemaleHodgkin DiseaseHumansImmunoconjugatesMaleMiddle AgedNivolumabRecurrenceT-Lymphocytes, RegulatoryBrentuximab VedotinChemokinesImmunoconjugatesNivolumab

Identifiers

PMID29229594
PMCPMC5855021
OpenAlexW2772084440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.